United Therapeutics

3D Systems DDD stocks are higher.

Posted on

According to Chuck Hull, 3D Systems CTO, “Over the last years as bioprinting and regenerative medicine have evolved, we’ve seen a growing need to place cells at high-resolution in a nurturing matrix to produce complex tissues. Precise 3D printing with hydrogels, followed by perfusion of cells into the printed scaffold is the best way to achieve this, and we are thankful our work with United Therapeutics has given us the opportunity to advance and perfect this technology.”

DDD Stock Alert: The Breakthrough That Has 3D Systems Stock Shooting Higher Today

This entry was posted in "AI Tech, Innovation, Robotics, 3D Printing, and Business.", "Cross-disciplinary Innovations: 3D Printing, 4D Printing, Biotechnology, and Robotics", "Evolution of Printing Technologies: Celebrating the Emergence of 3D/4D/5D Printing with Insights and Community Events", "Guidelines, Regulations, and SV3DPrinter.com Policy on Additive Manufacturing." and tagged , , , .

3D Bioprinting of tissues and organs

Posted on Updated on

CollPlant is a biotechnology company that develops and produces proprietary plant-based recombinant proteins for medical and aesthetic applications. The company specializes in developing plant-derived collagen for tissue engineering and regenerative medicine. CollPlant’s proprietary technology platform involves genetically engineering plants to produce human collagen, which can be used to create implantable tissues for various medical applications. CollPlant’s products are intended to address a range of medical conditions, including wound healing, orthopedics, and aesthetics.

According to Yehiel Tal, the Chief Executive Officer of CollPlant, “This fundraising is intended to support the advancement of our pipeline in the fields of medical aesthetics and 3D bioprinting of tissues and organs. We are now focused on facilitating our development programs of dermal fillers and regenerative breast implants. Our collaboration with United Therapeutics, which is using our BioInk technology for 3D printing lungs, is progressing, and we continue to expand our business collaborations with large international healthcare companies that seek to implement our revolutionary regenerative medicine technology. We are very pleased to have entered into this transaction with Mr. Sagi and the other investors.”

Eran Rotem, Deputy CEO & CFO. CollPlant Biotechnologies Raising $5.5 Million.

 

This entry was posted in "Additive Manufacturing Dynamics in 3D/4D Printing and AI Research Collaborations", "Cross-disciplinary Innovations: 3D Printing, 4D Printing, Biotechnology, and Robotics", "Guidelines, Regulations, and SV3DPrinter.com Policy on Additive Manufacturing.", "Optimizing Patient Treatment with Additive Manufacturing: Exploring 3D Printing in Healthcare" and tagged , , , , , , , , .